GlassScriptPhysician profile
Craig M Wax
NPI 1124072285
$6,173.81
in general payments reported to CMS, 2019-2025
28 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $757 · 2021: $815 · 2022: $1,029 · 2023: $668 · 2024: $1,081 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,602.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,290.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $880.22 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $496.69 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.02 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $240.92 | 2019-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $231.63 | 2019-2023 | |
| Amgen INC. | $182.25 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $155.27 | 2019-2023 | Steglatro, Steglujan |
| Stryker Corporation | $141.81 | 2025 | Everest Spinal System |
| Ibsa Pharma INC. | $131.90 | 2019-2025 | Licart, Tirosint, Flector |
| Novartis Pharmaceuticals Corporation | $89.21 | 2021-2025 | |
| Abbvie INC. | $87.71 | 2021-2023 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.82 | 2022-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $48.13 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $39.59 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $38.72 | 2020 | |
| Esperion Therapeutics, INC. | $29.42 | 2025 | Nexletol |
| Dexcom, INC. | $28.03 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $18.07 | 2025 | |
| Neotract INC. | $17.76 | 2019 | |
| Inspire Medical Systems, INC. | $16.18 | 2025 | Inspire |
| Astellas Pharma US INC | $14.35 | 2025 | Veozah |
| Intuity Medical INC | $14.35 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.52 | 2025 | Alvesco |
| Phathom Pharmaceuticals, INC. | $13.09 | 2025 | Voquezna |
| Phadia US INC. | $11.87 | 2021 | |
| Dermira, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Wax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.